mg98
Nucleic acidexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 1999 (NCT00003890)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA (cytosine-5)-methyltransferase 1ANTISENSE INHIBITOR
DNMT1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mg98
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003890 | Phase 1 | Feb 1, 1999 | Canadian Cancer Trials Group, Johns Hopkins University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 1999 |
2 organizations
Page 1 / 1